Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
March 28 2022 - 9:14AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of March 2022
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc
(the 'Company')
Publication of Notice of Annual General Meeting 2022
The Company has today published on its website (www.gsk.com/en-gb/investors/shareholder-information/annual-general-meeting/) the
Notice of Annual General Meeting ('AGM') 2022 (the '2022 AGM
Notice') which will be distributed to shareholders
shortly.
The Company's AGM will be held on Wednesday 4 May 2022 at 2.30pm at
the Sofitel London Heathrow, Terminal 5, London Heathrow Airport,
TW6 2GD and will also be broadcast live for shareholders to join
electronically. Full
details of how to join the meeting either in person or
electronically are contained in the 2022 AGM Notice and AGM
Guide.
In compliance with Listing Rule 9.6.1R of the UK Financial Conduct
Authority, the 2022 AGM Notice will be submitted to the
UK Listing Authority and will, in due course, be available for
inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
V A Whyte
Company Secretary
28 March 2022
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: March
28, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
